We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Monoclonal Antibody Blocks Development of Type I Diabetes in Mouse Model

By LabMedica International staff writers
Posted on 17 Jun 2015
Print article
Monoclonal antibody treatment prevented development of type I diabetes in a mouse model of the disease.

Type 1 diabetes is caused by an autoimmune reaction that destroys the pancreatic beta cells that produce insulin. The disease, which is currently treated by lifetime injections of insulin, is marked by pathologically elevated levels of sugar in the blood and urine that cause high rates of morbidity and mortality.

Investigators at The Hebrew University of Jerusalem (Israel) had previously identified a link between development of type I diabetes and the NKp46 receptor on the surface of NK (natural killer) immune cells. The NKp46 receptor is a member of the primary activating receptors of NK cells. This receptor was shown to recognize pancreatic beta cells, leading to their destruction by the immune system.

In the current study the investigators evaluated the potential therapeutic use of a monoclonal antibody intended to block the NKp46 receptor. They reported in the February 26, 2015, online edition of the journal PLoS One that their NCR1.15 antibody recognized the mouse homologue protein of NKp46, named Ncr1, and was able to down-regulate the surface expression of the NKp46 receptor on primary murine NK cells following antibody injection in vivo. Additionally, NCR1.15 treatments were able to down-regulate cytotoxic activity mediated by NKp46, but not by other NK receptors.

The investigators examined type I diabetes development in two models, non-obese diabetic mice and mice with a model of diabetes caused by low-dose streptozotocin. Results showed a significantly lower incidence of diabetic mice in the NCR1.15-treated group compared to control groups.

The Hebrew University of Jerusalem has signed an exclusive license agreement with the clinical-stage biopharmaceutical company BioLineRx (Jerusalem, Israel) to develop and commercialize the drug BL-9020 (NCR1.15) for the treatment of type I diabetes.

Related Links:
The Hebrew University of Jerusalem
BioLineRx


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Unit-Dose Packaging solution
HLX
New
Incubator
HettCube 120
New
Monkeypox Test
Monkeypox Virus Rapid Antibody Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.